 Brendan Frett
Concepts (163)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Protein Kinase Inhibitors | 23 | 2025 | 228 | 5.920 |
Why?
| | Proto-Oncogene Proteins c-ret | 12 | 2025 | 33 | 5.070 |
Why?
| | Drug Discovery | 12 | 2025 | 93 | 3.280 |
Why?
| | Antineoplastic Agents | 18 | 2025 | 1219 | 2.480 |
Why?
| | Neoplasms | 8 | 2025 | 1301 | 1.540 |
Why?
| | Pyridines | 6 | 2021 | 134 | 1.150 |
Why?
| | Drug Design | 9 | 2021 | 121 | 0.990 |
Why?
| | Small Molecule Libraries | 6 | 2021 | 67 | 0.990 |
Why?
| | Leukemia, Myeloid, Acute | 2 | 2024 | 202 | 0.900 |
Why?
| | Molecular Structure | 12 | 2025 | 315 | 0.880 |
Why?
| | Transforming Growth Factor beta | 2 | 2022 | 140 | 0.880 |
Why?
| | Structure-Activity Relationship | 13 | 2025 | 405 | 0.830 |
Why?
| | Cell Line, Tumor | 18 | 2025 | 1435 | 0.820 |
Why?
| | Gene Rearrangement | 1 | 2024 | 76 | 0.820 |
Why?
| | fms-Like Tyrosine Kinase 3 | 3 | 2021 | 20 | 0.790 |
Why?
| | Lung Neoplasms | 3 | 2024 | 633 | 0.770 |
Why?
| | Aminoquinolines | 1 | 2021 | 8 | 0.730 |
Why?
| | Receptor, trkA | 4 | 2024 | 7 | 0.730 |
Why?
| | Adenine | 1 | 2021 | 31 | 0.700 |
Why?
| | Pyrazoles | 2 | 2021 | 114 | 0.690 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2021 | 136 | 0.680 |
Why?
| | Imidazoles | 2 | 2018 | 124 | 0.670 |
Why?
| | Tumor Microenvironment | 1 | 2022 | 254 | 0.650 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 2 | 2020 | 38 | 0.640 |
Why?
| | Pyrimidines | 5 | 2024 | 200 | 0.540 |
Why?
| | ras Proteins | 2 | 2013 | 64 | 0.510 |
Why?
| | Dose-Response Relationship, Drug | 7 | 2025 | 1372 | 0.500 |
Why?
| | Computer-Aided Design | 1 | 2015 | 20 | 0.460 |
Why?
| | Humans | 34 | 2025 | 52513 | 0.460 |
Why?
| | Patents as Topic | 2 | 2025 | 10 | 0.440 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 6 | 1 | 2013 | 1 | 0.420 |
Why?
| | Proto-Oncogene Proteins | 2 | 2013 | 151 | 0.420 |
Why?
| | Animals | 15 | 2025 | 13464 | 0.420 |
Why?
| | Acetamides | 2 | 2025 | 19 | 0.410 |
Why?
| | Quinazolines | 2 | 2025 | 32 | 0.400 |
Why?
| | Cell Proliferation | 9 | 2025 | 1027 | 0.390 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 2 | 2024 | 106 | 0.380 |
Why?
| | HEK293 Cells | 4 | 2021 | 231 | 0.370 |
Why?
| | Models, Molecular | 4 | 2020 | 352 | 0.350 |
Why?
| | Receptor, trkB | 2 | 2021 | 6 | 0.330 |
Why?
| | Molecular Conformation | 3 | 2019 | 69 | 0.300 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2025 | 327 | 0.290 |
Why?
| | Receptors, Transforming Growth Factor beta | 2 | 2025 | 29 | 0.280 |
Why?
| | Mice | 9 | 2025 | 5943 | 0.270 |
Why?
| | Signal Transduction | 5 | 2022 | 1707 | 0.250 |
Why?
| | Drug Screening Assays, Antitumor | 6 | 2025 | 136 | 0.250 |
Why?
| | Molecular Docking Simulation | 3 | 2021 | 88 | 0.230 |
Why?
| | Ureteral Obstruction | 1 | 2025 | 62 | 0.230 |
Why?
| | Chromones | 1 | 2024 | 16 | 0.220 |
Why?
| | DNA-Activated Protein Kinase | 1 | 2024 | 21 | 0.220 |
Why?
| | Solubility | 1 | 2024 | 80 | 0.220 |
Why?
| | Morpholines | 1 | 2024 | 65 | 0.220 |
Why?
| | Phosphorylation | 4 | 2021 | 529 | 0.220 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2024 | 14 | 0.220 |
Why?
| | Proto-Oncogenes | 1 | 2024 | 27 | 0.220 |
Why?
| | NIH 3T3 Cells | 3 | 2021 | 52 | 0.210 |
Why?
| | Lymphoma | 1 | 2024 | 71 | 0.200 |
Why?
| | Drug Evaluation, Preclinical | 3 | 2021 | 142 | 0.200 |
Why?
| | Kidney Diseases | 1 | 2025 | 231 | 0.200 |
Why?
| | Mutation | 4 | 2022 | 1342 | 0.200 |
Why?
| | CARD Signaling Adaptor Proteins | 1 | 2022 | 6 | 0.190 |
Why?
| | Chemistry Techniques, Synthetic | 3 | 2020 | 21 | 0.190 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 169 | 0.190 |
Why?
| | Clinical Trials as Topic | 2 | 2021 | 472 | 0.190 |
Why?
| | Transfection | 1 | 2022 | 368 | 0.190 |
Why?
| | Indoles | 1 | 2024 | 276 | 0.180 |
Why?
| | Phthalazines | 1 | 2021 | 20 | 0.180 |
Why?
| | Thiophenes | 1 | 2021 | 46 | 0.180 |
Why?
| | Kidney | 1 | 2025 | 723 | 0.170 |
Why?
| | Cell Line | 3 | 2021 | 1030 | 0.170 |
Why?
| | Aziridines | 1 | 2020 | 1 | 0.170 |
Why?
| | Pyrroles | 1 | 2020 | 72 | 0.160 |
Why?
| | Maleimides | 1 | 2020 | 8 | 0.160 |
Why?
| | Protein Interaction Mapping | 1 | 2020 | 38 | 0.160 |
Why?
| | Ketones | 1 | 2019 | 9 | 0.160 |
Why?
| | Molecular Dynamics Simulation | 1 | 2019 | 44 | 0.160 |
Why?
| | Phosphoproteins | 1 | 2020 | 122 | 0.160 |
Why?
| | Adenosine Triphosphate | 1 | 2020 | 209 | 0.160 |
Why?
| | Oligopeptides | 1 | 2019 | 92 | 0.150 |
Why?
| | Oxidative Stress | 1 | 2024 | 809 | 0.150 |
Why?
| | Apoptosis | 3 | 2022 | 1120 | 0.150 |
Why?
| | Decarboxylation | 1 | 2018 | 3 | 0.150 |
Why?
| | Receptor, trkC | 1 | 2018 | 4 | 0.150 |
Why?
| | Metabolome | 1 | 2019 | 102 | 0.150 |
Why?
| | Models, Chemical | 1 | 2018 | 66 | 0.150 |
Why?
| | Mice, Nude | 2 | 2017 | 235 | 0.150 |
Why?
| | Isoquinolines | 1 | 2018 | 24 | 0.150 |
Why?
| | Bone Marrow | 1 | 2020 | 363 | 0.150 |
Why?
| | Computational Biology | 1 | 2020 | 211 | 0.150 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2018 | 33 | 0.140 |
Why?
| | Benzimidazoles | 1 | 2018 | 50 | 0.140 |
Why?
| | Software | 1 | 2020 | 280 | 0.140 |
Why?
| | Heterocyclic Compounds | 1 | 2018 | 29 | 0.140 |
Why?
| | Boronic Acids | 1 | 2018 | 183 | 0.140 |
Why?
| | Ligands | 2 | 2015 | 207 | 0.140 |
Why?
| | Proteomics | 1 | 2020 | 327 | 0.140 |
Why?
| | Nitrazepam | 1 | 2016 | 1 | 0.130 |
Why?
| | Glioblastoma | 1 | 2017 | 97 | 0.120 |
Why?
| | Libraries, Digital | 1 | 2015 | 2 | 0.120 |
Why?
| | Molecular Weight | 1 | 2015 | 80 | 0.120 |
Why?
| | Carboxylic Acids | 1 | 2015 | 18 | 0.120 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2015 | 102 | 0.110 |
Why?
| | Colorectal Neoplasms | 1 | 2018 | 295 | 0.110 |
Why?
| | Palladium | 1 | 2014 | 4 | 0.110 |
Why?
| | Brain Neoplasms | 1 | 2017 | 290 | 0.110 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2013 | 21 | 0.110 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 69 | 0.100 |
Why?
| | Molecular Targeted Therapy | 1 | 2013 | 133 | 0.090 |
Why?
| | Cells, Cultured | 1 | 2014 | 1587 | 0.090 |
Why?
| | Cell Survival | 2 | 2021 | 602 | 0.070 |
Why?
| | Mice, Inbred BALB C | 2 | 2020 | 310 | 0.070 |
Why?
| | Protein Binding | 2 | 2020 | 671 | 0.070 |
Why?
| | Rats | 2 | 2025 | 3181 | 0.060 |
Why?
| | Neoplasms, Experimental | 1 | 2025 | 112 | 0.060 |
Why?
| | Fibrosis | 1 | 2025 | 197 | 0.060 |
Why?
| | Administration, Oral | 1 | 2025 | 455 | 0.050 |
Why?
| | Female | 5 | 2025 | 28219 | 0.050 |
Why?
| | Guanylate Cyclase | 1 | 2022 | 9 | 0.050 |
Why?
| | DNA Damage | 1 | 2024 | 307 | 0.050 |
Why?
| | Oncogenes | 1 | 2022 | 60 | 0.050 |
Why?
| | T-Lymphocytes | 1 | 2024 | 327 | 0.050 |
Why?
| | Furans | 1 | 2022 | 30 | 0.050 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2022 | 87 | 0.050 |
Why?
| | Smad Proteins | 1 | 2021 | 16 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2022 | 448 | 0.040 |
Why?
| | Blood-Brain Barrier | 1 | 2021 | 49 | 0.040 |
Why?
| | Binding, Competitive | 1 | 2020 | 90 | 0.040 |
Why?
| | Wound Healing | 1 | 2022 | 219 | 0.040 |
Why?
| | Amino Acid Motifs | 1 | 2020 | 59 | 0.040 |
Why?
| | Hematopoiesis | 1 | 2020 | 71 | 0.040 |
Why?
| | Workflow | 1 | 2020 | 50 | 0.040 |
Why?
| | Binding Sites | 1 | 2021 | 377 | 0.040 |
Why?
| | Xenopus laevis | 1 | 2019 | 44 | 0.040 |
Why?
| | Mice, Inbred C57BL | 1 | 2025 | 1897 | 0.040 |
Why?
| | Databases, Genetic | 1 | 2020 | 83 | 0.040 |
Why?
| | Protein Structure, Secondary | 1 | 2019 | 71 | 0.040 |
Why?
| | Ethanol | 1 | 2022 | 340 | 0.040 |
Why?
| | Stereoisomerism | 1 | 2019 | 101 | 0.040 |
Why?
| | Cell Movement | 1 | 2020 | 275 | 0.040 |
Why?
| | Mass Spectrometry | 1 | 2020 | 293 | 0.040 |
Why?
| | Catalytic Domain | 1 | 2018 | 61 | 0.040 |
Why?
| | Cell Cycle Checkpoints | 1 | 2018 | 32 | 0.040 |
Why?
| | Aza Compounds | 1 | 2018 | 14 | 0.040 |
Why?
| | Enzyme Activation | 1 | 2018 | 269 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2017 | 86 | 0.030 |
Why?
| | Gene Silencing | 1 | 2017 | 120 | 0.030 |
Why?
| | Polyploidy | 1 | 2016 | 9 | 0.030 |
Why?
| | M Phase Cell Cycle Checkpoints | 1 | 2016 | 5 | 0.030 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 1 | 2016 | 9 | 0.030 |
Why?
| | Male | 3 | 2025 | 26816 | 0.030 |
Why?
| | Neoplastic Stem Cells | 1 | 2017 | 93 | 0.030 |
Why?
| | Protein Conformation | 1 | 2016 | 178 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2016 | 222 | 0.030 |
Why?
| | Hydrazines | 1 | 2015 | 18 | 0.030 |
Why?
| | Solvents | 1 | 2015 | 33 | 0.030 |
Why?
| | Metals | 1 | 2015 | 37 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 1 | 2018 | 1543 | 0.030 |
Why?
| | Carbon | 1 | 2015 | 55 | 0.030 |
Why?
| | Microwaves | 1 | 2014 | 10 | 0.030 |
Why?
| | Catalysis | 1 | 2014 | 89 | 0.030 |
Why?
| | Kinetics | 1 | 2015 | 622 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2013 | 168 | 0.020 |
Why?
| | Models, Biological | 1 | 2013 | 740 | 0.020 |
Why?
|
|
Frett's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|